Introduction of cancer stem cell research
The concept of cancer stem cells (CSCs), which is considered to be one of the milestones in our understanding of cancer, 1 was first proposed 80 years ago (1937) for leukemia. 2 While key experiments were performed in the 1960s and 1970s, [3] [4] [5] it was not until the 1990s that the first CSCs were isolated, initially from leukemia. 6, 7 This was followed by the identification of putative stem cells in a range of solid tumors, first in breast cancer, 8 then in brain, 9 prostate, 10 head and neck, 11 pancreas, 12 colon, 13 mesenchymal, 14 and lung cancer. 15 CSCs are the only tumor cells showing the capability to self-renewal and multi-potent differentiation usually found in stem cells. These abilities of CSCs are often condensed to "stemness" which gives rise to the assumption that CSCs derive from mutated stem cells, indicating that the CSCs model resolves many previously debated issues. 16, 17 CSCs developed different mechanisms to evade and resist therapies. DNA repair is more efficient in CSCs in contrast to differentiated tumor cells. 18 This might explain, at least in part, why radiation or chemotherapy does effect CSCs only poorly. In general, CSCs feature a high basal level of genomic instability finally leading to higher resistance to Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells therapy, initiation of regression and metastasis, and is linked to a poor prognosis. 19 Furthermore, high expression of ATPbinding cassette (ABC) transporters, which transport chemotherapeutics to the cell membrane for exocytosis 20 ; an increase of aldehyde dehydrogenase (ALDH) accompanied with high levels of detoxification; or the accumulation of anti-apoptotic proteins might account for a restricted success of chemotherapy. 21 However, the concept of CSCs is not without controversy, 22 and, importantly, CSCs should not be confused with the cell of origin, 23 but with its hierarchical order, it emphasizes the view of tumors as complex ecological systems which act along strict Darwinian principles found in ecology and population genetics. While it has been proposed that the cells of origin are tissue stem cells or progenitor cells, 24, 25 this view is not universally accepted 26 and recent modeling data can be seen to support the notion that any tissue cell should be drawn as putative cell of origin giving rise to CSCs. 27 An alternative model, shown by us 28 and others [29] [30] [31] to be potentially applicable for glioblastoma stem cells, postulates that differentiated (tumor) cells can de-differentiate to stem cells, in essence completely separating the concepts of CSCs and cell of origin. Interestingly, while de-differentiation has also been observed to occur in normal tissue cells, 32 it takes place at a much higher frequency within populations of differentiated cancer cells. 33 Taken together, CSCs are heterogenic cell populations from different origin, which have not been fully elucidated yet, and present many mechanisms explaining resistance to cancer therapy and recurrence. In the next section, we will discuss autophagy and their potential targets to interfere with the survival of CSCs.
Autophagy and its dual role in cancer development
Cells need specific mechanisms to respond to extra-and intracellular stresses such as nutrient starvation, changes in insulin concentrations, growth factor levels, endoplasmic reticulum (ER) stress, or hypoxia. Autophagy is an intracellular recycling process that transports damaged proteins and organelles to the lysosome for degradation. The degraded proteins are then transported back into the cytosol and can be metabolized to energy carriers. Autophagy is not only a response to cell stress but also maintains homeostasis in healthy cells by eliminating damaged organelles, such as peroxisomes and mitochondria. 34 Autophagy is a (patho-)physiological process which occurs in both healthy and malignant cells and can act as a tumor-suppressing or tumor-promoting (oncogenic) factor. 35 In case of tumor suppression, autophagy protects from accumulation of reactive oxygen species (ROS), damaged proteins, or organelles by degradation, thereby maintaining cellular homeostasis. Accumulation of ROS can lead to DNA damage and genomic instability and by this means supports tumorigenesis. Thus, autophagy prevents healthy cells from cancer development. 36 Furthermore, autophagy is important by the fact that monoallelic loss of the autophagy gene encoding Beclin1 increases the risk of human ovarian, breast, and prostate tumors. 37 However, more recent studies questioned a distinct role of Beclin1 in tumor growth. 38 Nevertheless, defects in other autophagyassociated genes (e.g. ATG5) are linked to cancer. 35 Once tumor cells are established, autophagy can be tumor-promoting by protecting malignant cells from stressors and facilitates their survival. If the tumor reaches a diameter larger than 1-2 mm, angiogenesis is essential to supply tumor cells with nutrition and oxygen. However, tumor-induced neoangiogenesis is normally incomplete, de facto tumor cells suffer from hypoxia and subsequent metabolic stress. CSCs are often located in a hypoxic core region of a tumor and have to fight against consequences of oxygen shortage. 39, 40 Interestingly, hypoxia plays a crucial role in regulating autophagy since the absence of oxygen leads to inhibition of mammalian target of rapamycin complex 1 (mTORC1) and subsequent decreased inhibition of the unc-51 like autophagy activating kinase 1 (Ulk1) complex finally resulting in activation of autophagy. Consequently, application of anti-angiogenic drugs, which lead to hypoxia, can be cytotoxic for tumor cells but might also generate adapted and even more potent CSCs as demonstrated by Conley et al. 41 for breast CSCs.
Another important role of autophagy in CSCs is linked to the Warburg effect. The Warburg effect demonstrates a hallmark of cancer development since all tumor cells upregulate their levels of aerobic glycolysis and reduce mitochondrial energy supply. Consequently, the metabolic process rises and autophagy provides CSCs with necessary nutrients and supports metabolic reconfiguration. 42, 43 In addition, autophagy supports metastasis since the performance of autophagy protects detached cells from anoikis which is a form of programmed cell death. 44 However, there is evidence that high autophagic activity can diminish CSCs by excessive degradation of organelles and proteins. 35 This underlines the assumption that autophagy plays a dual role in tumorigenesis.
Different types of autophagy pathways
There are several types of autophagy pathways: microautophagy, macroautophagy, chaperone-mediated autophagy, pexophagy, mitophagy, and xenophagy. [45] [46] [47] Of these, macroautophagy is the best-known autophagy mechanism being involved in antigen presentation and is therefore a potential target for cancer therapy. 48 During the process of macroautophagy, cytoplasmic constituents are separated by a double membrane forming the autophagosome by fusing with the lysosome to build the autolysosome. The enclosed content can be degraded by lysosomal proteases mostly cathepsins. 49, 50 Microtubule-associated proteins (MAPs) 1A/1B light chain 3 (LC3) and ubiquitin-binding protein p62 (sequestosome 1, p62) play a critical role in autophagy and serve as common indicators for the autophagic flux. LC3-I is processed to LC3-II by the cytosolic cysteine protease autophagy-related 4 (ATG4) and is covalently conjugated to phosphatidylethanolamine which is located at the outer autophagosome membrane. Thereby, LC3-II accumulates and represents an early marker for autophagy. 51, 52 p62 directs polyubiquitinated protein aggregates to the autophagosome via binding to LC3-I. As a result, the protein aggregates and p62 and LC3-II are also degraded by resident cathepsins. A decrease of p62 indicates autophagic degradation and is a marker for the late stage of autophagy. 51, 53, 54 Inhibition of autophagy leads to an accumulation of p62 which subsequently interferes with tumor proliferation by deregulation of NF-kB signaling or by an increase in ROS. 55 In this section, we will focus on the regulation of autophagy.
Regulation of autophagy
Mutations in the core autophagy signaling cascade, that is, in the Atg genes, have been found to be associated with several groups of disorders (metabolic, pulmonary, infectious, vascular, neurodegenerative diseases as well as cancer 56 ). While dysregulation of proteins involved in autophagy has been demonstrated for several cancers, such as hepatocellular carcinoma, endometrial adenocarcinomas, and colorectal cancer, 57 no study has yet found similar aberrations in glioblastoma. However, the PI3K/Akt/mTOR signaling cascade is activated in almost 90% of all glioblastoma, predominantly via inactivation (frequently mutated in cancer cells) of its negative regulator PTEN. 58 Macroautophagy is regulated by the presence or absence of intra-and extracellular stressors like intracellular metabolic stress, nutrient starvation, hypoxia, growth factor deprivation, and stress related to the ER. [59] [60] [61] Inhibition of autophagy under favorable conditions (presence of amino acids, growth factors, oxygen, and glucose) is usually mediated via two major components, namely, cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA) and mTORC1. 62 Active PKA and mTORC1 inhibit autophagy processes by phosphorylating Ulk1 and Ulk2, thereby preventing Ulk1/Ulk2-complex formation and subsequent autophagosome formation. 63, 64 There is a crosstalk between the stemness-related pathways (Wnt/β-catenin, Hedgehog, and Notch) and the regulation of autophagy on different levels. A recent report showed that autophagy leads to degradation of Notch1, thereby influencing stem cell differentiation. Knockdown of autophagy-regulating components like ATG7 or ATG16L1 resulted in increased levels of Notch, the transcription factor fragment notch intracellular domain (NICD), and its target gene Hes1. Consequently, in neuronal cultures prepared from mice with partial loss of function of the Atg16L1 gene, more stem cells could be found in comparison to wild-type mice. 65 Conversely, Natsumeda et al. 66 observed that pharmacological inhibition of Notch leads to protective induction of autophagy in glioma neurospheres finally resulting in chemoresistance.
Targeting the autophagy pathway
Autophagy can have tumor-promoting capacity in tumor cells; an optimal drug combines the ability to target autophagy and is selective for CSCs. However, one obstacle of standard drugs is specificity since CSCs and stem cells share the same surface markers, survival signals, DNA repair, self-renewal, and differentiation mechanisms. Examples of autophagy inhibitors are chloroquine (CQ) and hydroxychloroquine (HCQ), known as anti-malarial drugs exhibiting anti-tumor capacity by preventing autophagosomal maturation and inhibition of lysosomal degradation 67, 68 (Table 1 ). Administration of CQ and HCQ is promising in autophagy-targeting therapy, and some studies are currently under way to investigate the effects of supplementing conventional anti-cancer therapy with CQ/ HCQ. 90 Furthermore, the epidermal growth factor (EGF) receptor is a target in CSC therapy, thereby showing promising clinical results in epithelial as well as head and neck cancer when combined with conventional therapies. 91 For a long time, plant-derived natural compounds are used as alternative medicine and described as potential anti-cancer drugs. Curcumin, an extract of turmeric (Curcumin longa), was reported to regulate autophagy via elevated levels of LC3-II and Beclin1 finally leading to autophagosome formation. 92, 93 Resveratrol, a phytoalexin found among grapes, induces Beclin1-independent autophagy in breast cancer cells by inhibition of Akt/protein kinase B (PKB)-mediated phosphorylation and mTOR signaling. 94 Similarly, the flavonoid quercetin, occurring in many fruits and vegetables, is known to trigger the accumulation of hypoxia-inducible factor-1α (HIF-1α) by blocking mTOR signaling. 95, 96 Thus, plant-derived natural extracts are promising components in targeting autophagy and do not require time-and money-consuming approval.
In the next part, we will have a closer look into glioblastoma stem cell development, their resistance to treatment, and tumor recurrence which is the most serious challenge in glioblastoma research. Furthermore, we will elucidate the proteolytic machinery of glioblastoma stem cells and how these cells can escape immune detection.
A novel cathepsin-based therapeutic approach that reduces MHC I-mediated immune evasion in glioblastoma stem cells
Glioblastoma Glioblastoma, also known as astrocytoma grade IV, is the most common and aggressive tumor of the central nervous system characterized by rapid cell proliferation, high vascularity, and diffuse invasion of the surrounding healthy tissue. The current therapeutic approach after diagnosis comprises neurologically safe maximal surgical removal and courses of both radio-and chemotherapy. 97, 98 Although many novel treatment strategies have been investigated in the last decade following the addition of the chemotherapeutic drug temozolomide 99 to the standard treatment protocol, most of them have led to no significant therapeutic improvement or-in the case of bevacizumab-have yielded rather controversial results. 100 This is, at least partially, due to the presence of the blood-brain barrier limiting the application of many drugs as well as genetic alterations causing resistance to multimodal therapy approaches, leaving a limited range of treatment options that only prolong survival and quality of life for a few months. 101 Therefore, despite intense efforts, glioblastoma remains one of the most lethal tumors with a mean patient survival of 14.6 months. 102 Besides increased apoptotic resistance, there are several other cellular aspects that make glioblastoma a highly lethal and difficult-to-treat disease: Glioblastoma grows diffusely and highly invasive, thereby infiltrating the surrounding brain tissue and making localized treatment, for example surgery, particularly ineffective. For example, after surgical removal tumor recurrence manifests within 2-3 cm of the resection cavity wall in more than 95% of cases. 103 Furthermore, systemic chemotherapy and whole brain irradiation have so far proven insufficient to eradicate invasive cells and micrometastasis. 104 This might be due, at least in part, to invading cells associated with the anatomic structures and increased apoptotic resistance. [105] [106] [107] Crucially, the presence of these invasive glioblastoma stem cells 108 is sufficient to cause progressive neurologic dysfunction. The central role of proteolysis in tumor progression has long been established and extensively described. Several classes of proteases (metalloproteases, and cysteine-, aspartic-, serine proteases) have been identified and shown to destroy the tissue structure surrounding the invasive and-by extension-metastatic process. 109 Even though glioblastoma lacks the ability of most malignant tumors to metastasize to distant sites, motility and invasion of glioblastoma stem cells are a defining feature of malignancy. Upon clinical presentation, glioblastoma stem cells have invariably spread and infiltrated large areas of the brain. 110 We recently described a mechanism whereby glioblastoma stem cells re-model their microenvironment to be more permissive toward invasion 111 : Stress-induced NF-κB activates matrix metalloproteinases (MMPs) via the conversion of plasminogen to plasmin by the proteolytic performance of urokinase-type plasminogen activator (uPA). This, in turn, allows for the effective processing of fibronectin which is then incorporated into a tumor-specific matrix. In essence, our work postulates that the role of proteolysis in glioblastoma stem cell invasion is not limited to the destruction of obstacles in the paths of invading cells and the truncation of tethering points which might otherwise retain tumor cells in the bulk structure but leads to the formation of novel fibronectin "roads." These protect glioblastoma stem cells from detrimental influences, such as anoikis, and provide a route along where glioblastoma stem cells can transverse the brain. 111 Recent data clearly indicate that established cell lines used as experimental surrogates for glioblastoma poorly reflect the in vivo situation in terms of gene and protein expression. 112, 113 Furthermore, these cell lines also lack some key features of glioblastoma when used in orthotopic animal models; no micrometastasis can be observed when using U87MG cells, one of the few cell lines that are actually tumorigenic when used in xenotransplants. 28 Culturing primary patient material as spheroids stably preserves tumor expression patterns allowing short-term expansion under adherent conditions. 114 Importantly, these cells are also able to recapitulate the patients' tumor in a murine environment. 115 Letting spheroid cultures differentiate into adherent cells allows us to examine the different types of cancer cells present in a tumor. In addition to the various lineages of differentiated cells obtained, one can also assess the behavior of CSCs or tumor-initiating cells. 116, 117 Glioblastoma stem cells are suggested to emerge from neural stem cells or partially from differentiated progenitor cells and are characterized by stem cell markers, such as Sox-2, Nestin, Musashi, and the disputed CD133. However, the latter certainly does not identify the most stem cell-like population in glioblastoma, 118, 119 and recent work of Schneider et al. 28 shows that a high-level state of plasticity exists between the stem cell and differentiated phenotypes. Nevertheless, glioblastoma stem cells are highly resistant to treatment, partially due to the high expression of the multidrug resistance ABC transporter protein breakpoint cluster region pseudogene 1 (BCRP1), DNA repair proteins, and gene products that inhibit apoptosis. Furthermore, these cells are frequently not within the cell cycle, are not eradicated by conventional treatment, and most likely contribute to recurrence. 120 
The importance of cathepsins in tumorigenesis and glioblastoma cells
Lysosomal cathepsins play an essential role in proteome homeostasis by catalyzing the degradation of proteins for proper recycling of amino acids. In addition, cathepsins are responsible for proteolytic maturation of antigens to antigenic peptides for an efficient antigen presentation to the major histocompatibility complex (MHC). Most cathepsins are intracellular proteases, active in an acidic environment, and their expression level varies depending on the cell type. However, a dysfunction of the proteolytic activity of cathepsins is associated with various pathophysiological processes. 121 Cysteine cathepsins of the C1A subfamily are monomeric enzymes with a molecular weight between 20 and 35 kDa. Cathepsin C is the only papain-like protease which significantly exceeds the characteristic size of the subfamily due to its tetrameric composition (200 kDa). 122 C1A cysteine cathepsins contain cathepsin B (CatB), -C, -F, -H, -K, -L, -O, -S, -V, -W, and -X. These enzymes are mainly active within the endosomes and lysosomes and are involved in protein turnover together with the aspartic proteases CatD and CatE. 123 CatG belongs to the class of serine proteases (S1) and is found in azurophilic granules of neutrophils 124, 125 and primary antigen-presenting cells (APCs). 126, 127 The G refers to its capability to degrade globulins of the α-, β-, and γ types. 128 The 28-kDa human CatG has both chymotrypsin-and trypsin-like activity and is active in a broad pH range (pH 5-8; optimum at neutral pH). 129 During activation, among other proteases, CatG is released by neutrophils at the site of inflammation to initiate and support an immune response. 129, 130 According to their common role in proteolytic degradation, an uncontrolled cathepsin activity, particularly of cysteine cathepsins, can lead to a majority of clinical disorders, including tumors. Consequently, the regulation of high cathepsin activity to a steady-state level by specific protease inhibitors is an encouraging tool to interfere with tumorigenesis. 131, 132 The acidic extracellular environment of tumor cells is ideal for the proteolytic activity of cathepsins since most of the cathepsins have their highest activity in a slightly acidic condition and are often found outside of tumor cells. Subsequently, they activate growth factors and proteases or degrade components of the extracellular matrix. 133 For example, CatB is involved in the function of MMPs which leads to the detachment of cells and thus to the initiation of the cell migration process. 134 In addition, CatB is responsible for survival and growth of tumor cells, activation of signaling pathways of angiogenesis; 135 converts pro-uPA to uPA; 136 and inactivates MMP inhibitors, such as tissue inhibitors of metalloproteinase (TIMP1 and TIMP2) which are important for migration of tumor cells. 137 The protein level of CatB occurs to be ten times higher in glioblastoma in contrast to low-grade glioma or normal brain tissue. Furthermore, high levels of CatB correlate with invasiveness of glioblastoma cells. 138, 139 Conversely, levels of natural cysteine protease inhibitors are downregulated in glioblastoma. 140 Indeed, inhibition of CatB by the selective CatB inhibitor CA074 in glioma cells reduced invasiveness of these cells. 141 We used three pairs of previously described, distinct patientderived cell populations, each pair consisting of stem cells and genetically identically, but epigenetically diverse differentiated cells. 142 These cells, termed SC35, SC38, and SC40, were obtained from two male patients and one female patient, between the ages of 44 and 75 years at the time of diagnosis, and are shown to grow invasive in our murine xenotransplant model. 28 The general observation that high CatB levels are characteristic for glioblastoma cells 138 was confirmed in glioblastoma stem cells from several patients (SC35, 38, and 40), differentiated glioblastoma cells (PC35, 38, and 40), and glioblastoma cell lines (A172, U87). 143 Similar to CatB, levels of CatL are higher in glioblastoma cells and responsible for glioblastoma cell invasion. 144 CatS is also known to be highly expressed in tumor cells; for instance, CatS is involved in microtubule formation and enhances the collagenolytic activity which accounts for tumor invasion. 145, 146 In fact, CatS is upregulated in astrocytoma cells suggesting a crucial role of CatS in invasion of these cells. 147 Until now, only little information has been acquired regarding CatH. Lower amounts have been found in lung cancer while there are higher levels existing in sera of lung cancer patients 148 and in glioblastoma cells, 149 and similar findings were described for CatK which is highly expressed in glioblastoma cells. 150 The activity of cysteine proteases is regulated by many factors including endogenous inhibitors of the cystatin family. Lower cystatin expression levels like for cystatin C (CysC) are associated with tumor progression. It has been reported that cystatins decrease with malignant invasiveness of glioblastoma cells. 151 To this end, it is plausible to target cathepsin activity in glioblastoma stem cells to avoid recurrence of glioblastoma. Modulating of their proteolytic activity by specific protease inhibitors is a logical consequence and might interfere with viability, proliferation, and migration. On time, a huge variety of selective protease inhibitors are available and summarized in 121 and Sienczyk and Oleksyszyn. 152 Notably, it is important that such protease inhibitors are applicable to restore the balance of cathepsin activity in glioblastoma cells since the disruption of the functional properties of cathepsins supports tumorigenesis.
In order to gain a better insight why glioblastoma stem cells are not recognized and eliminated by immune cells, which is also called immune evasion, the immune system will be specified in more details in the following section.
MHC I-mediated immune evasion mechanisms of glioblastoma stem cells
Natural killer (NK) 153 cells are bone marrow-derived large granular lymphocytes and involved in the defense of viral infections as well as the destruction of tumor cells. [154] [155] [156] Due to the lack of clonal antigen receptors, NK cells are traditionally counted to the innate immune system. However, recent evidence suggests that they have a long-term memory to certain antigens and can adapt to the environment by releasing cytokines. 157 NK cells are characterized by their ability to initiate apoptosis in target cells without the necessity of MHC-mediated antigen presentation. An absence of MHC I on the target cell surface is recognized by NK cells resulting in an NK-driven cytolysis ("missing-self" recognition). 156 In turn, NK cells are not activated by the inspected cell when cell surface MHC I-or non-classical MHC molecules are present on the cell surface. 156 More precisely, NK cells express the killer inhibitory receptor (KIR) on the cell surface which can bind to MHC I molecules and inhibit NK cell activation, whereas the natural killer cell receptor protein 1 (NKR-P1) probably recognizes a modified glycocalyx and retains NK cells activated. Activated NK cells secrete perforins from granules which penetrate the plasma membrane of the target cell and subsequently polymerize a cylindrical transmembrane pore leading to osmotic lysis. Thereby, the target cell will be eliminated. 158, 159 A T cell-mediated immune response is qualified by recognition of pathogen-derived antigens presented by APCs and non-immune cells. While these antigens (peptides) are recognized by CD8 + cytotoxic T lymphocytes (CTLs) when bound to MHC I, CD4 + T helper cells inspect MHC II when presented by professional APCs. Activated CTLs can eliminate target cells by different mechanisms, on one hand, by releasing perforins and granzymes, which leads to the activation of the caspase cascade resulting in apoptosis, and, on the other hand, by secreting cytokines mainly interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α). Both cytokines play an important role in inhibition of viral replication, promotion of MHC-mediated antigen presentation, and activation of the immune system. 160, 161 The T cell receptor (TCR) of CD8 + and CD4 + T cells recognizes antigens bound to the binding groove of MHC molecules. Endogenous antigens such as viral proteins or defective ribosomal translation products are proteolytically degraded by the proteasome and transported to the lumen of the ER by the transporter associated with antigen presentation (TAP). 162 In the ER lumen, antigens are further processed to a length of 8-9 amino acids by amino peptidases. The ER lumen is also the place of MHC I folding and assembly. After binding of peptides to nascent MHC I molecules, the MHC I peptide complex is transported to the cell surface via the Golgi network. MHC I molecules are heterodimers composed of a polymorphic α-chain, which is associated with a β2-microglobulin chain. They are encoded by the three classical loci human leukocyte antigen-A (HLA-A), HLA-B, and HLA-C. 160, 163 MHC class II glycoproteins are responsible for the cell surface presentation of exogenous antigens which are previously processed in the endocytic compartment by the concerted action of cathepsins. MHC II molecules (HLA-DQ, HLA-DP, and HLA-DR) are mainly expressed in professional APCs, such as B cells, dendritic cells (DCs), and macrophages. 160 APCs are also able to present extracellular antigens to CD8 + T cells by MHC I molecules, and intracellular antigens can be presented to CD4 + T cells by MHC II molecules. This phenomenon is named cross-presentation and is important to recruit CD8 + T cells in response to endocytosed viral-and tumor-derived antigens. The latter plays a crucial role in tumor immune surveillance. 164 Since it is not completely clear how cross-presentation is accomplished, several mechanisms are currently discussed. Cell surface MHC I molecules can be endocytosed (recycling pathway), MHC I molecules in the ER traffic to the trans-Golgi network (TGN) and then to the cell surface or to the endocytic compartment (vacuolar pathway), or reach the phagosome where MHC I are loaded with a new round of exogenous or endocytic antigens and reach the cell surface for inspection by CTLs or are degraded by a yet to be identified protease. [165] [166] [167] [168] We found that in these pathways, MHC I molecules can be degraded by CatG (Figure 1 ). 143 The autophagosome arranges the delivery of cytosolic proteins to the MHC II antigen-presenting pathway by merging with the MHC II loading compartment. 169 The pathological cell surface reduction of MHC I, which causes an impaired immune response, is an immune evasion mechanism by several viruses, for instance, immune deficiency virus (HIV-1) and tumor cells. 156 In HIV-1-infected cells, HIV-1-derived Nef protein prevents the cell surface expression of MHC molecules which accumulate in the intracellular space. 170, 171 Similarly, invading glioblastoma stem cells reduce newly synthesized MHC I cell surface expression which diminishes tumor-associated antigen presentation and elimination by CTLs. 172, 173 However, glioblastoma stem cells still maintain a limited set of MHC I presumably to escape from recognition by NK cells. 156 Recently, we demonstrated that MHC I molecules are catalytically degraded by CatG in vitro and in peripheral blood mononuclear cells (PBMCs) in contrast to glioblastoma stem cells. In order to determine whether the absence of CatG in glioblastoma stem cells might be the reason of complete downregulation of MHC I, levels of MHC I were analyzed in CatGoverexpressing glioblastoma stem cells (Figure 2) . Indeed, MHC I was effectively downregulated when CatG was introduced in glioblastoma stem cells. In addition, the amount of intracellular MHC I was also reduced confirming that MHC I is proteolytically degraded by CatG and is responsible for reduced cell surface expression of MHC I in CatG-expressing cells. 143 Even though CatG is an essential protease for post-transcriptional regulation of MHC I molecules, glioblastoma stem cells do not have the ability to proteolytically degrade MHC I by CatG which prevents the complete reduction of cell surface MHC I to avoid recognition by NK cells. Restoration of CatG in glioblastoma might be a supportive therapeutic opportunity by using oncolytic viruses 174 loaded with a CatG encoding gene which possibly sensitizes glioblastoma stem cells to be targeted by NK cells.
Conclusion and further perspectives
Autophagy is a process that ensures nutrient supply and homeostasis in the presence of stressors and supports cell survival. The main problem in targeting autophagy is the similarity between glioblastoma stem cells and normal stem cells. In healthy cells, autophagy acts tumor-suppressive by maintaining homeostasis. In cancer cells; however, autophagy can act in either a tumor-promoting (oncogenic) or tumor-suppressing manner, and the imbalance between these dictates the outcome of cell survival. 35 Lysosomal cathepsins control the proteome steady state by catalyzing protein degradation; however, a dysfunctional or uncontrolled cathepsin activity can cause harm. Distinct cathepsins are upregulated in tumor cells; of these, increased CatB activity correlates with glioblastoma stem cell mobility, and the obvious consequence to inhibit CatB activity impaired the invasiveness of glioblastoma stem cells. Furthermore, levels of MHC I are regulated by the proteolytic performance of CatG. On the other hand, glioblastoma stem cells do not harbor CatG allowing a limited set of MHC I molecules on the cell surface to escape NK cell recognition. Cathepsin inhibitors or activators, for instance, lactoferrin, which is a natural CatG activator as published by us just recently, 175 or bioactive tripeptides, which increase CatG activity, 176 might reduce high cathepsin activity found in glioblastoma stem cells or reinstall such cathepsins necessary for supportive immune recognition. 
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